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Based on a number of experiments it is concluded that the fluorescein labeled β-heptapeptide fluoresceinyl-NH-CS-(S)-β3hAla-(S)-β3hArg-(R)-
β3hLeu-(S)-β3hPhe-(S)-β3hAla-(S)-β3hAla-(S)-β3hLys-OH translocates across lipid vesicle bilayers formed from DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine). The conclusion is based on the following observations: (i) addition of the peptide to the vicinity of micrometer-sized giant vesicles
leads to an accumulation of the peptide inside the vesicles; (ii) if the peptide is injected inside individual giant vesicles, it is released from the vesicles in a
time dependent manner; (iii) if the peptide is encapsulated within sub-micrometer-sized large unilamellar vesicles, it is released from the vesicles as a
function of time; (iv) if the peptide is submitted to immobilized liposome chromatography, the peptide is retained by the immobilized DOPC vesicles.
Furthermore, the addition of the peptide to calcein-containing DOPC vesicles does not lead to significant calcein leakage and vesicle fusion is not
observed. The finding that derivatives of the β-heptapeptide (S)-β3hAla-(S)-β3hArg-(R)-β3hLeu-(S)-β3hPhe-(S)-β3hAla-(S)-β3hAla-(S)-β3hLys-OH can
translocate across phospholipid bilayers is supported by independent measurements using Tb3+-containing large unilamellar vesicles prepared from egg
phosphatidylcholine andwheat germ phosphatidylinositol (molar ratio of 9:1) and a corresponding peptide that is labeled with dipicolinic acid instead of
fluorescein. The experiments show that this dipicolinic acid labeled β-heptapeptide derivative also permeates across phospholipid bilayers. The possible
mechanism of the translocation of the particular β-heptapeptide derivatives across the membrane of phospholipid vesicles is discussed within the frame
of the current understanding of the permeation of certain oligopeptides across simple phospholipid bilayers.
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Currently, there is considerable interest in peptides that are able
to translocate across the membranes of biological cells, since such
“cell penetrating peptides” (CPPs) are potentially interesting for
delivering bioactive molecules into cells [1–4]. It seems that the
mechanism bywhich the peptides are taken up by the cells depends
on the type of CPP and different internalization pathwaysmay exist
simultaneously [2], although endocytosis appears to be the major
route of uptake [4]. Furthermore, the importance of the chemical
structure of the counter ions for efficient cell internalization has also
been pointed out and experimentally demonstrated [5].
One class ofCPPs areα-oligoarginines [6] and β-oligoarginines
[7] and corresponding derivatives thereof. In the latter case, uptake
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[8]was found to occur for example in the case of peptide 1 (Fig. 1),
which is a β-decaarginine peptide derivative that contains a fluo-
rescein group for visualization by fluorescence microscopy. In
contrast, no cell uptake was observed for 3, the fluorescein
derivative of the β-heptapeptide 2 (Fig. 1) [8]. Like 1, β-peptide 3
also bears a fluorescein group, but overall 3 is considerably more
hydrophobic than 1. Furthermore, 3 does not form a helix- or turn-
secondary structure in solution [9] due to the altered configuration
at the third β-amino acid ((R)-β3hLeu), in comparison to all other
amino acids being in an (S) configuration. The same applies for
peptides 2 and 4.
Preliminary experiments with giant unilamellar vesicles
(GUVs) formed from POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)]) at a molar ratio of 9:1 (POPC:POPG)
indicated that the two peptides also behave differently if added to
these types of membrane-mimicking systems [8]. While 1 bound
to the negatively charged vesicle membrane, 3 appeared to pass
across the vesicle bilayer into the interior of the vesicles [8].
Therefore, 3 seemed to be taken up by simple POPC vesicles but
not by biological cells [7,8]. These initial experimental findings in
cell culture and vesicle studies may indicate at least the following.
Either (i) the uptake of 3 by biological cells is not a simple dif-
fusion of this peptide derivative across the lipid matrix of the
membrane; or (ii) simple POPC/POPG vesicles are not adequate
models of the lipid matrix of the membranes of the biological cells
with which the peptide uptake was tested.
In any case, a strong binding of β-oligoarginines to negatively
charged phospholipid bilayers as found for1 has been confirmed in
a series of independent mechanistic and thermodynamic measure-Fig. 1. Chemical formulae of the four β-peptide derivatives used in this study, 1–5. 1: flu
β3hPhe-(S)-β3hAla-(S)-β3hAla-(S)-β3hLys-OH; 3: fluoresceinyl-NH-CS-(S)-β3hAla-(S
(S)-β3hAla-(S)-β3hArg-(R)-β3hLeu-(S)-β3hPhe-(S)-β3hAla-(S)-β3hAla-(S)-β3hLys-OH;
acid (pyridine-2,6-dicarboxylic acid); 6: [(S)-β3hArg]8-NH2.ments using submicrometer-sized vesicles, and a comparison with
corresponding α-oligoarginines was carried out [10]. The binding
data suggested that ∼70–75% of the total free energy of binding
has non-electrostatic origin (hydrogen bonding and/or hydropho-
bic interactions) [10].
In the present work, the focus is on peptide derivative 3 and the
related dipicolinic acid derivative 4 (Fig. 1), in comparison with
peptide derivatives 1 and 5 (Fig. 1). In a series of independent
experiments we particularly show that the two types of β-peptide
derivatives (3 and 4 vs. 1 and 5) behave differently if brought in
contact with zwitterionic or negatively charged vesicles. Evidence
is presented that 3 and 4 permeate across DOPC (1,2-dioleoyl-sn-
glycero-3-phospholcholine) and mixed egg phosphatidylcholine
(egg PC)/wheat germ phosphatidylinositol (PI) bilayers, while
there is no indication of bilayer permeation in the case of 1 or 5.
2. Materials and methods
2.1. Chemicals
1, 2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoly-sn-
glycero-3-phosphocholine (POPC), N-NBD-PE (N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)phosphatidylethanolamine), N-rhodamine-PE (N-(lissamine rhodamine B sul-
fonly)phosphatidylethanolamine) and egg phosphatidylethanolamine (egg PE) were
purchased from Avanti Polar Lipids (Albaster, AL, USA). Egg phosphatidylcholine
(egg PC) grade 1 and wheat germ phosphatidylinositol (PI) were purchased from
Lipid Products (Nutfield, UK). Calcein was bought from Dojindo (Kumamoto,
Japan). Melittin was from Sigma (St. Louis, MO, USA). TbCl3 hexahydrate was
purchased fromAldrich. Sepharose 4 B, Sephacryl S-1000 and Sephadex G-25 PD-
10 were from Amersham Biosciences, Sweden. ANTS (8-aminonaphthalene 1,3,6-
trisulfonic acid sodium salt) and DPX (p-xylylene bis(pyridinium) bromide) were
from Molecular Probes (Indian City, OR, USA). All the other chemicals were of
analytical grade.oresceinyl-NH-CS-[(S)-β3hArg]10-NH2; 2, (S)-β
3hAla-(S)-β3hArg-(R)-β3hLeu-(S)-
)-β3hArg-(R)-β3hLeu-(S)-β3hPhe-(S)-β3hAla-(S)-β3hAla-(S)-β3hLys-OH; 4: DPA-
5: DPA-[(S)-β3hArg]8-NH2. FL and DPA stand for fluorescein and dipicolinic
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The peptides 1, 2, 3, 5 and 6 were prepared as described previously [8,11].
Peptide derivative 4was synthesized as follows. In a first step, the preparation of
Fmoc-protected β-heptapeptide bound toWang resin was achieved by using Fmoc-
protected β-amino acids as obtained from Fluka (Switzerland) or Novabiochem
(Switzerland). Esterification of Wang resin (300 mg, 1.1 mmol/g) and subsequent
peptide synthesis was carried out according to our previously published procedure
[8] to give 565 mg of resin-bound Fmoc-protected β-heptapeptide. A portion of the
resin (125 mg) was Fmoc-deprotected using 20% piperidine in dimethylformamide
(DMF) (4 ml, 4×5 min) under N2 bubbling, and the resin was filtered and washed
with DMF (4 ml, 5×1 min). The resin was then treated with a solution of pyridine-
2,6-dicarboxylic acidmonobenzyl ester [11] (54mg, 0.21mmol),HATU (=2-7-Aza-
1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (76 mg,
0.20mmol) andDIPEA (=N,N′-diisopropylethylamine) (71ml, 0.42mmol) inDMF
(5ml) and the suspensionmixed by N2 bubbling for 4 h. The resin was washed with
DMF (5ml, 3×1min) and CH2Cl2 (5 ml, 5×1 min) and completion of the coupling
was confirmed with TNBS (2,4,6-trinitrobenzene sulfonic acid) [12]. The resin was
then dried under high vacuum for 12 h. Cleavage of the peptide from the resin was
carried out by suspending the dry peptide–resin in a solution of TFA/i-Pr3SiH/H2O
(95:2.5:2.5, v/v/v, 10ml) andmixing byN2 bubbling for 4 h. The resin was removed
by filtration, washedwith TFA (2×), and the filtrate diluted with CH2Cl2 (10ml) and
the volatiles removed under reduced pressure. The resulting oily residue was treated
with cold Et2O to precipitate the crude benzyl-protected peptide. The benzyl-
protected DPA-peptide (DPA=dipicolinic acid=pyridine-2,6-dicarboxylic acid)
was dissolved in MeOH (5 ml) under N2, and Pd/C (10% w/w) was added. The
apparatuswas evacuated and flushedwithH2 (3×), and the solutionwas stirred under
H2 (balloon) for 12 h. The solution was filtered through Celite, and the filtrate was
concentrated under reduced pressure to give 53 mg of crude peptide. Purification of
25 mg of the crude peptide by RP-HPLC (25% 0.1% TFA in H2O, 75%MeCN for
5 min, 25–30% 0.1% TFA in H2O in 30 min, linear gradient) and subsequent
lyophilization with a Helosicc cooling condenser and a high vacuum pump
gave 7.1mgof pure 4 aswhite TFA salt. For theRP-HPLCpurification, a preparative
C18-HPLC column (Nucleosil 100-7 C18, 250 mm×21 mm) from Marchery-Nagel
(Switzerland) was used at a flow rate of 10 ml/min with UV detection at 220 nm.
The product was characterized by analytical RP-HPLC (25% 0.1% TFA in
H2O, 75% MeCN for 5 min, 25–30% 0.1% TFA in H2O in 30 min, linear
gradient): retention time=9.2 min, purityN98%. MALDI-MS 1061.5 (16, [M+
K]+), 1025.6 (19), 1024.6 (59), 1023.6 (100, [M+H]+), 512.3 (4, [M+2H]2+),
511.8 (3). HR-MS: 1023.5965 ([C50H79N12O11]
+; calc. 1023.5991). Analytical
RP-HPLCwas performed using a Nucleosil 100-5 C18 column (250 mm×4mm)
fromMachery-Nagel (Switzerland) at a flow rate of 1 ml/min with UV detection
at 220 nm. For MS, a IonSpec Ultima 4.7-T-FT Ion cyclotron resonance (ICR,
HR-MALDI, in 2,5-dihydroxybenzoic acid matrix) spectrometer was used; data
are given in m/z (% of basis peak).
2.3. Preparation of giant unilamellar vesicles (GUVs)
POPC and DOPC GUVs were prepared with the electroformation method [13],
originally developed by Angelova and Dimitrov [14–16]. The investigation
chamber contained two parallel platinium wire electrodes (diameter 0.5 mm),
separated at a distance of 3 mm.
POPC GUVs were prepared as follows: About 2 μl of a solution of POPC
(0.25 mM) in diethyl ether:methanol (9:1, v/v) were applied onto each of the two
platinum wires. After drying, 1 ml deionized water was added and an alternating
electric field was applied at 1.2 V and 2 Hz for 30–50 min to hydrate the phos-
pholipids and to form the giant vesicles.
The vesicles were observed with a Zeiss Axiovert 135 TV inverted microscope
with a 20× objective with long distance Achroplan lenses and a DIC filter, equipped
with aHamamatsuC5810CCDcamera and aHB-50mercury excitation light source
and the Zeiss filter set no. 9.
DOPC GUVs were prepared as follows: About 2 μl of a solution of DOPC
(0.1 mM) in diethyl ether:methanol (9:1, v/v) were applied onto each of the two
platinum wires. After drying, 1 ml deionized water was added and an alternating
electric fieldwas applied at 1.5Vand 10Hz for 120min to hydrate the phospholipids
and to form the giant vesicles. The alternating electric fieldwas generatedwith a SG-
4101 function generator from IWATSU Co. Ltd., Osaka, Japan.The vesicles were observed with an Olympus IX-51-11 FL/PH-S fluorescence
microscope and anORCA-ERC4742-95CCD camera fromHamamatsu Photonics.
2.4. Addition of peptides to POPC GUVs
A 2-μl aliquot of an aqueous solution of the peptide (100 μM or 200 μM) was
added from a distance of 10–50 μm away from the target vesicle by using an
Eppendorf 5242 microinjector, as described previously [8].
2.5. Injection of peptides into DOPC GUVs
Aqueous solutions of the peptides (200 μM) were microinjected into individual
GUVs, using a microinjector IM-300 (Narishige Co. Ltd., Tokyo, Japan) following
the previously described method [13,17,18]. For each peptide, four independent
measurements were carried out with target vesicles that had diameters above
100 μm. The injected volumes varied between ca. 5 and 20 picoliters [13]. The
images taken were analyzed with the software Aqua Cosmos, version 2.5.
2.6. Preparation of DOPC large unilamellar vesicles (LUVs)
LUVs with an average diameter of ca. 100 nm were prepared by the extrusion
technique [19] using a LiposoFast device from Avestin (Canada) [20]. A thin dried
film containing 10 mg DOPC (13.4 μmol) was hydrated with 1 ml buffer solution
(0.1MTris–HCl, 0.15MNaCl, pH 7.5) by shaking for 60min and then vortexed for
30 s at room temperature to yield a vesicle suspension containing mainly
multilamellar vesicles. After freezing the sample in liquid nitrogen and thawing at
room temperature (five times), the suspension was first passed through a 200-nm
polycarbonate membrane (15×), and then through a 100-nm polycarbonate mem-
brane (15×), to yield LUVs. The average hydrodynamic diameter of the vesicles was
between 110 and 115 nm, as determined by dynamic light scattering measurements
using a DLS-700Ar instrument from Otsuka Electric Co., Ltd., Osaka, Japan. The
DOPC concentration in the final vesicle suspension was determined with an enzy-
matic assay kit (Test Wako-C) from Wako Pure Chemical Co. Ltd. (Osaka, Japan).
2.7. Calcein release experiments with DOPC LUVs
DOPC LUVs containing calcein (0.1 M) were prepared in a similar manner to
that described above for LUVs in pure buffer solution, with the only difference being
that the solution with which the lipids were hydrated was 0.1 M Tris–HCl, pH 7.5,
containing 0.1 M calcein. Untrapped calcein molecules were removed from the
calcein-containing vesicles by size exclusion chromatography using a Sepharose 4B
column (diameter: 1 cm, length: 15 cm; applied sample volume: 0.5 ml), see [21],
and 0.1 M Tris–HCl, 150 mM NaCl, pH 7.5 as elution buffer. The fluorescence
intensity of the vesicles containing entrapped calcein was measured and found to be
low due to self-quenching [22,23].
To follow the release of entrapped calcein after peptide addition, a peptide solution
was mixed with a DOPC LUV suspension to yield 0.1 mM DOPC and 10 μM
peptide. The change in fluorescence intensity due to calcein release from the vesicles
[23] was monitored with a FP6500 fluorescence spectrometer from Nihon Bunko,
Japan. Excitation and emissionwavelengthswere set at 490 and 520 nm, respectively.
The amount of calcein released after time t was calculated according to Eq. (1)
RFð%Þ ¼ 100ðIðtÞ  Ið0ÞÞ=ðIðlÞ  Ið0ÞÞ ð1Þ
where RF is the percentage amount of calcein released, I(0), I(t) and I(∞) are the
fluorescence intensities measured at the beginning of the experiment, at time t, and
after addition of 3% triton X-100, respectively.
2.8. Peptide release experiments with DOPC LUVs
DOPC LUVs containing peptides were prepared in a similar manner to that
described above for LUVs in pure buffer solution, but using as the lipid hydrating
solution 0.1 M Tris–HCl, 0.15 M NaCl, pH 7.5 containing 10 μM peptide.
Untrapped peptidemolecules were removed from the peptide-containing vesicles by
size exclusion chromatography using Sephacryl S-1000 (diameter: 1 cm, length:
15 cm; applied sample volume: 0.5 ml) and 0.1MTris–HCl, 150mMNaCl, pH 7.5
as elution buffer. The peptide-containing LUV suspension was stored for 2 days at
2729T. Shimanouchi et al. / Biochimica et Biophysica Acta 1768 (2007) 2726–2736room temperature and then re-chromatographed (sample volume: 1 ml) to check for
any released peptide molecules.
2.9. Immobilized liposome chromatography (ILC)
Lipid vesicles can be immobilized covalently or non-covalently on gel beads for
use as a hydrophobic affinity matrix for HPLC systems [24,25]. In the present work,
DOPC LUVs were covalently immobilized on Sephacryl S-1000 gel beads,
following the procedures described in the literature using LUVs containing 1 mol%
egg PE [26]. Sephacryl S-1000 was activated with p-nitrophenyl chloroformate and
reacted with the LUVs [26]. The gel beads were then packed into a HR5/5 glass
column from Amersham Biosciences (Sweden) [21]. The inner diameter of the
column was 0.5 cm and the length was 5.2 cm. The amount of phospholipids
immobilized onto the gel beads was 2 μmol per mg gel, the flow rate was 0.25 ml/
min, 10 μl of a 0.5-μM peptide solution was injected onto the column, and 0.1 M
Tris–HCl (pH 7.5) containing 0.15 M NaCl was used as eluent.
2.10. Fusion assays with DOPC LUVs
The possible fusion of DOPC LUVs upon peptide addition was investigated
with three different fusion assays. While two of the assays were based on measuring
the mixing of the aqueous contents of two separately prepared vesicle populations,
the third assaywas based onmonitoring themixing of lipids originally present in two
different vesicle populations.
2.10.1. Cobalt (II)–calcein method
The assay was carried out as described previously [27,28]. In brief, 0.1 mM
DOPC LUVs containing the non-fluorescent cobalt(II)–calcein complex (internal
concentration 0.8 mM) and 0.1 mM DOPC LUVs containing EDTA (internal
concentration 1mM)weremixed. After addition of 10 μMpeptide, the fluorescence
intensity was measured (λex=490 nm, λem=520 nm). If EDTA complexes Co
2+, the
sample becomes fluorescent. The extent of fusion can be calculated by using Eq. (2)
Fusionð%Þ ¼ j100ðIðtÞ  Ið0ÞÞ=ðIðlÞ  Ið0ÞÞj ð2Þ
where I(t) and I(0) are the fluorescence intensities measured at time t and 0,
respectively, and I(∞) is the fluorescence intensity measured after addition of triton
X-100 (0.5 wt.%).
2.10.2. ANTS/DPX method
The assay was carried out as previously described [29]. In brief, 0.1 mMDOPC
LUVs containing 12.5 mM ANTS and 20 mM NaCl, and 0.1 mM DOPC LUVs
containing 45 mM DPX, 20 mM NaCl, 5 mM HEPES (4-(2-hydoxyethyl)
piperazine-1-ethanesulfonic acid), pH 7.5 were first prepared separately. The eluent
in the final size-exclusion chromatography step was 5 mMHEPES, 100 mMNaCl,
pH 7.5. EDTA (1mM)was added to the vesicles to yield a concentration of 0.1mM.
The peptide was then added at a concentration of 10 μM. The decrease in
fluorescence intensity resulting from the formation of the ANTS/DPX complex
(λex=355 nm, λem=520 nm) was monitored and the extent of fusion was calculated
by applying Eq. (2).
2.10.3. N-NBD-PE/N-rhodamine-PE resonance energy transfer assay
The assay was carried out as previously described [29]. LUVs at a concentration
of 0.1 mM DOPC containing 1 mol% N-NBD-PE and LUVs at a concentration of
0.1mMDOPC containing 1mol%N-rhodamine-PEwere prepared separately. Both
vesicle preparations were mixed with unlabeled LUVs at a molar ratio of labeled to
unlabeled vesicles of 1:4. Finally, equal volumes of the two 0.1-mM vesicle
suspensions were mixed and 10-μM peptide was added. Immediately after mixing
(t=0), the fluorescence intensity was monitored (λex=460 nm, λem=530 nm). If the
lipids of the different sets of vesicles exchange, the energy released by NBD is
transferred to rhodamine resulting in an increase in rhodamine fluorescence intensity.
Quantitative lipid mixing was determined by using LUVs that contained 0.1 mol%
of N-NBE-PE as well as 0.1 mol% N-rhodamine-PE.
2.11. Preparation of Tb3-containing egg PC/PI (9/1) LUVs
Tb3+-containing lipid vesicles were prepared from TbCl3 hexahydrate
(0.2 mmol) and 100 mg egg PC/PI (9:1, molar ratio) by extrusion through200 nm polycarbonate membranes, as described previously [30]. External Tb3+ was
separated from the vesicles on a Sephadex G-25 PD-10 desalting column by elution
with 0.2 MNaCl. The concentration of Tb3+ inside the aqueous pool of the vesicles
was between 5 and 7 mM [30]. Tb3+-containing vesicles were used within a few
hours.
The average size and the size distribution of the vesicle preparations were
analyzed by dynamic light scattering with a Zetasizer 3000 HSA (from Malvern
Instruments, Malvern, UK). Tb3+-containing vesicles showed an average mean
hydrodynamic diameter between 140 and 180 nm.
2.12. Tb3+-based bilayer permeation assay
The entry kinetics of the peptides 4 and 5 into the Tb3+-containing aqueous
interior of the vesicles were determined on a SynergyHT plate reader (fromBio-Tek
Instruments, Winooski, VT, USA) [31]. The vesicle suspensions were diluted to 2–
3mg phospholipid/ml in 0.2M Tris–HCl, pH 6.8. All solutions were equilibrated at
25 °C. At time zero, 10 to 20 μl of 0.5 to 1 mM peptide solutions were added to the
wells of a 96-well plate which each contained 200 μl of the diluted vesicle sus-
pension. The total Tb3+ concentrationwas ca. 0.1mMand the peptide concentrations
were between 20 and 100 μM. The samples were excited at 275 nm, and Tb3+
luminescencewas recorded every 30 s at 545 nmwith a time delay of 0.05ms, a gate
time of 1 ms, a cycle time of 20 ms and at 1 flash per cycle. The assays were run for
30 to 60 min. The apparent logarithmic permeation coefficient, log Permapp, was
calculated from the luminescence vs. time curves, as described previously [31].
The luminescence vs. time profiles were fitted with a bi-exponential function.
The initial, fast phase, which reached about half of the fitted infinite luminescence,
was used to calculate Permapp as shown in Eq. (3):
Permapp ¼ k  r=3 ð3Þ
where k is the rate constant of the initial, fast phase and r is the hydrodynamic
diameter of the vesicles, as determined by dynamic light scattering. The applicability
conditions and further details of this procedure are discussed elsewhere [31].
2.13. Circular dichroism (CD) measurement
CD spectra were recorded on either a Jasco J-710 or a Jasco J-820SFU
spectropolarimeter from 195 to 250 nm at 25 °C using 1 mm quartz cells.
Measurements inmethanol were carried out at 0.2 mM and smoothing of the spectra
was done by using the Jasco software. Measurements in water were performed at
0.01 mM peptide and in the absence or presence of DOPC LUVs at a DOPC
concentration of 0.1 mM. All spectra are normalized.3. Results
3.1. Interaction of 1 and 3 with POPC GUVs and leakage of 3
from DOPC GUVs
In a series of preliminary measurements with negatively
chargedGUVs composed of POPC and POPG (9:1,molar ratio), it
was previously found that the two fluorescent peptides 1 and 3
behave very differently if added in the external vicinity of a target
vesicle [8]. The analysis of fluorescence lightmicrographs showed
that the β-decaarginine derivative 1 binds to the vesicles without
any evidence of permeation into the vesicle's interior under the
experimental conditions used [8]. In contrast, externally added 3
appeared to translocate across the negatively charged bilayer into
the interior of the vesicles [8]. If zwitterionic POPC GUVs were
used without any added negatively charged lipid, there was again
evidence that 3 permeated across the vesicle bilayer from the
vesicle's exterior to the interior, although the uptake process
seemed to be slightly slower than that observed with POPC:POPG
(9:1) vesicles (data not shown). In contrast, no indication of
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observed in the case of 1 (data not shown).
With DOPC GUVs, microinjection experiments were per-
formed. A few picoliters of a 200-μM peptide solution were
microinjected inside individual giant vesicles, and the fluores-
cence intensity of the targeted vesicle wasmonitored as a function
of time after microinjection. The results obtained for 1 and 3 are
shown in Fig. 2. In the case of the β-decaarginine derivative 1, the
fluorescence remained stable for at least 40 min (Fig. 2Ab and B,
open square), indicating that the injected peptide did not leak out
from the vesicle. In contrast, the fluorescence intensity of the
vesicles intowhich peptide derivative 3was added decreased withFig. 2. Microinjection of peptides 1 and 3 into DOPC giant vesicles. (A) Fluorescence
or peptide derivative 1 (b) was injected. The length of the bar corresponds to 100 μm.
and 40 min. (B) Changes in relative fluorescence intensity (in arbitrary units) as obtain
of either 1 (open square) or 3 (filled circle). The values given are mean values and St
that had a diameter between 100 and 150 μm. The concentration of the peptide in the s
20 picoliters.time (Fig. 2Aa and B, filled circles), indicating peptide leakage
from the vesicles.
3.2. Leakage of 3 from DOPC LUVs
LUVs that contained 3 or 1 were first prepared at a con-
centration of 10 μM peptide and 13.4 mM DOPC. In a first
approximation, one can assume that the concentration of the
peptides inside the vesicles immediately after removing non-en-
trapped peptides was about 10 μM (assuming equal peptide distri-
bution between vesicle interior and bulk aqueous phase during
vesicle preparation). The vesicle suspensions were then stored atmicroscope images of individual GUVs into which either peptide derivative 3 (a)
The images were recorded immediately after microinjection, and after 10, 20, 30
ed from the analysis of the fluorescence microscopy images after microinjection
andard deviations from four independent measurements carried out with vesicles
olution that was injected was 200 μM. The injected volumes were between 5 and
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Sephacryl S-1000 column. The collected fractions were analyzed
for the presence of peptide. Fig. 3A (for 3) and B (for 1) show for
both peptide derivative (a) the chromatograms obtained immedi-
ately after preparation in which non-entrapped peptides (2) were
separated from the peptide-containingDOPCLUVs (1), and (b) the
chromatogram of the pooled vesicle-fractions (1) that were stored
for 2 days and then re-chromatographed. In the case of 3, free
peptide molecules were present in the stored samples, indicatingFig. 3. Encapsulation of 10 μM peptide derivatives 3 (A) and 1 (B) inside DOPC
LUVs and peptide release from DOPC LUVs, as determined by size exclusion
chromatography using a Sephacryl S-1000 column (diameter: 1 cm; height 15 cm).
Elution buffer: 0.1 M Tris–HCl, 0.15 M NaCl, pH 7.5, fraction volume: 0.5 ml. The
upper chromatograms (a) show the separation of peptide-containing vesicles (peak 1)
fromnon-encapsulated peptide (peak 2), carried out after the encapsulation procedure
(applied volume: 0.5 ml). The pooled fractions of peak 1 were stored for 2 days at
room temperature and then applied (1 ml) onto the same column (bottom chro-
matograms (b)).
Fig. 4. Immobilized liposome chromatographic behavior of the peptide derivatives 3
and 1 in comparison with glycine. Sephacryl S-1000 modified with covalently
bound DOPC-LUVs (see Materials and methods). Column diameter: 0.5 cm,
column length: 5.5 cm; 2 μmol lipids/mg gel; flow rate: 0.25 ml/min; sample
applied: 10μl 0.5μMpeptide; elution buffer: 0.1MTris–HCl, 0.15MNaCl, pH7.5.peptide leakage from the LUVs during storage. For 1, no leakage
could be observed under the conditions used (no presence of free
peptide in Fig. 3Bb).
3.3. Immobilized liposome chromatography
DOPC LUVs were covalently bound to Sephacryl S-1000 gel
beads [24–26] and the immobilized lipid vesicles were used as an
insoluble matrix to study the affinity of the peptide derivatives 1
and 3 for the vesicles by the so-called “immobilized liposome
chromatography” [25,32]. Fig. 4 shows the elution profiles for 3
and 1 in comparison with glycine. While glycine and 1 were not
retarded, both eluting after about 15 min, 3 clearly interacted with
the immobilized vesicles and eluted after about 20 min, indicating
a stronger association of 3 with DOPC vesicles than of 1.
3.4. Calcein release experiments
DOPC LUVs containing 0.1 M self-quenched calcein [22,23]
were prepared at a DOPC concentration of 13.4 mM and the
release of the entrapped calcein upon external addition of the
peptides 1 and 3 was investigated at pH 7.4 (0.1 M Tris–HCl,
0.1 M NaCl) with a total concentration of 0.1 mM DOPC and
10 μMpeptide.Within the first 10min after peptide addition to the
vesicles, no significant calcein release could be observed. In
contrast, upon addition of 10 μMmelittin, a polypeptide known to
permeabilize phospholipid bilayers [33], 100% of the entrapped
calcein was released after 3 min (Fig. 5).
3.5. Vesicle fusion assays
Peptide derivatives 3 and 1 were tested for their vesicle fusion
ability using DOPC LUVs (0.1 mM DOPC) and a peptide con-
centration of 10 μM. For this, three different assays were used, the
cobalt(II)-calcein method [27,28], the ANTS/DPX method [29],
and the N-NBD-PE/N-rhodamine-PE resonance energy transfer
assay [29].Whilewith the first twomethods vesicle fusion resulting
in mixing of aqueous contents can be monitored, with the third
method vesicle fusion resulting in phospholipid mixing can be
Fig. 5. Time course of calcein leakage from DOPC LUVs after addition of peptide
derivative 1 (□), peptide derivative 3 (●), or melittin (○) at 25 °C. Calcein concen-
tration during vesicle preparation: 0.1 M; [DOPC]=0.1 mM; [peptide]=10 μM.
Fig. 6. Uptake experiments with the Tb3+-based permeation assay. Representative
luminescence vs. time curve after adding 24 μM 4 to Tb3+-containing LUVs
composed of egg PC and wheat germ PI (molar ratio 9:1) at 25 °C. Similar kinetic
curves were also observed for peptide concentrations up to 100 μM. Lipid concen-
trations were between 2 and 3 mg/ml. Grey line: control in the absence of peptide.
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icant vesicle fusion was found under the conditions used (Table 1).
3.6. Entry of 4 into egg PC/PI (9/1) LUVs
To corroborate the observed phospholipid bilayer permeation
capability of the β-heptapeptide derivative 3, the permeation be-
havior of 4 was also studied with a recently developed Tb3+-based
permeation assay [11,30,31]. As shown in Fig. 6, the luminescence
of the entrapped Tb3+-ions increased with time after peptide addi-
tion to Tb3+-containing LUVs, indicating that 4 entered the egg PC/
PI (9:1, molar ratio) vesicles. The determined logarithmic apparent
permeation coefficient, log Permapp, for 4 was −8.3±0.1 (cm/s).
With egg PC LUVs, peptide uptake could neither be detected
with 4, nor with 5 (Fig. 1) (data not shown).
3.7. CD measurements
The CD spectra of 2 and 6 measured at a concentration of
0.2 mM in methanol are shown in Fig. 7A. While 6 has aTable 1
Extent of vesicle fusion caused by the peptide derivatives 3 and 1 as measured
with DOPC LUVs and three independent fusion assays, see Fusion assays with
DOPC LUVs for the experimental details









Cobalt(II)–calcein method 1.1±0.5 0.8±0.4 0.8±0.4
ANTS/DPX method 2.3±1.5 1.2±0.8 0.9±0.3
N-NBD-PE/N-rhodamine- PE
resonance energy transfer assay
0.1±0.8 0.2±0.2 0.4±0.2
[DOPC]=0.1 mM, [peptide]=10 μM. The extent of fusion was determined
20 min after peptide addition using Eq. (2). Each measurement was carried out
four times. Mean values with standard deviations are given.negative CD signal centered around 215 nm, in agreement with
what has been found before in the case of 0.1 mM 6 [8], the CD
spectrum of peptide 2 is rather different, indicating that 2 doesFig. 7. A: Normalized CD spectra of 2 (a) and 6 (b) in methanol. The peptide
concentration was 200 μM. B: Normalized CD spectra of 1 and 3 recorded at 25 °C
in the absence and in the presence of DOPCLUVs. a: 1 in water; b: 1 in the presence
of DOPCLUVs; c: 3 in water, d: 3 in the presence of DOPCLUVs; e: DOPCLUVs.
The peptide concentration was 10 μM and the concentration of DOPC 0.1 mM.
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spectra characteristic for secondary structures, see [9].
In the case of 1 and 3, the CD spectra weremeasured in aqueous
solution in the absence and presence of DOPC LUVs, see Fig. 7B.
In the case of 1, the CD spectrum in the presence of vesicles (b) is
almost the same as in purewater (a), with a broadminimumaround
220 nm. For 3, however, the presence of DOPC LUVs leads to a
significant change in the CD spectrum (compare curves c and d in
Fig. 7B), indicating peptide vesicle interactions that lead to
conformation changes of peptide 3.
4. Discussion
Despite there being no experimental evidence for the
permeation of 3 across biological membranes [7,8], experiments
with lipid vesicles indicate that this molecule can permeate across
simple phospholipid bilayers present in the form of vesicles. In
contrast, the β-decaarginine derivative 1, known to be taken up by
biological cells [7,8], only binds to the surface of phospholipid
vesicles, without any indication of a translocation across the bi-
layered vesicle membrane [8].
The initial findings that 3 translocates across negatively
charged GUVs composed of POPC and POPG (at a molar ratio
of 9:1) [8] correlates with the observation that 4 enters
negatively charged LUVs composed of egg PC and PI (9:1,
molar ratio) (Fig. 6). Independent of whether fluorescein or
dipicolinic acid is covalently bound to the terminal amino group
of the β-heptapeptide, the peptide permeates across negatively
charged phospholipid bilayers. Since fluorescein and dipicolinic
acid both are partially hydrophobic moieties, it may well be that
these labels contribute to the observed uptake by the vesicles,
although they may not be made responsible alone for the up-
take: peptide derivative 1 –which bears a fluorescein group – is
not taken up by the same type of vesicles. The determined
logarithmic permeation coefficient for 4 (−8.3±0.1 (cm/s)) is
similar to that of the much shorter hydrophobic β-tetrapeptide
DPA-(R)-β3hVal-(S)-β3hAla-(R)-β3hVal-(R)-β3hVal-OH (log
Permapp=−8.3±0.2 cm/s for egg PC LUVs, [11]). Although 4
is longer and more hydrophilic than the β-tetrapeptide derivative
to which comparison is made, both peptide derivatives permeate
similarly. We originally thought that the permeation coefficient
should decrease with an increase of peptide length and a
decrease of its hydrophobicity, as previously discussed and de-
monstrated in the case of model α-peptides [34,35] and β-
peptides [11]. The positive charges of 4 may lead to an efficient
permeation across net negatively charged bilayers because the
peptide may interact electrostatically with PI that may not only
affect the affinity to the membrane but also lead to a change in
the peptide conformation on the membrane surface, resulting in
a better translocation.
In the case of pure zwitterionic phosphatidylcholine bilayers,
the permeation of 3 was less efficient but still detectable. In
contrast, there was no measurable uptake of 4 by egg PC LUVs
under the experimental conditions used. This qualitative differ-
ence in the behavior of 3 and 4 may be due to the different
hydrophobicities of fluorescein and DPA, fluorescein being more
hydrophobic than DPA.In a series of experiments, the permeation behavior of 3 was
studied with DOPC vesicles and a comparison was made with the
behavior of 1 under comparable conditions. The physico-chemical
properties of DOPC bilayers have been studied to some extent in
the past. X-Ray and neutron diffraction data, for example, have
shown that aDOPCbilayer has a “dynamic thickness”with respect
to the transbilayer separation of water, suggesting that there must
be transient contacts between the two cis-double bonds in DOPC
andwater [36]. It has been argued that the effective thickness of the
hydrocarbon core of aDOPC bilayer can be less than 28.6Åwhich
lowers the energy barrier for the bilayer penetration and
translocation of relatively polar molecules [36].
All our experiments indicate that 3 can permeate across DOPC
bilayers while 1 cannot. The results are summarized as follows: (i)
if the peptide derivatives 3 or 1 were microinjected into DOPC
GUVs, leakage of 3 from the vesicles was observed, while 1
remained trapped (Fig. 2); (ii) the same was observed with DOPC
LUVs containing encapsulated peptides (Fig. 3); (iii) an affinity of
3 to DOPC vesicles was clearly demonstrated by immobilized
liposome chromatography (Fig. 4),while 1 did not showan affinity
for the vesicles. The interaction of 3withDOPC vesicles leads to a
detectable change of the CD spectrum (Fig. 7B).
Although the mechanism of bilayer translocation of 3 remains
to be elucidated, there are at least two peptide properties that may
be key factors for the observed peptide translocation: (i) the ab-
sence of secondary structure (no 314 helix or turn formation in
solution [9]), and (ii) “intermediate” hydrophobicity. A hydropho-
bic peptide is expected to partition from the vesicle's internal or
external aqueous phase into the bilayer. However, if the peptide is
too hydrophobic, it will remain trapped within the membrane,
partitioning being in favor of the hydrophobic membrane domain.
3 seems to have an optimal hydrophobicity for bilayer trans-
location,while 1 is too hydrophilic. The presence of the fluorescein
group in 3 may contribute to this optimal hydrophobicity [37].
The proposed mechanism for the translocation of 3 across the
bilayers of phospholipid vesicles is based on the partitioning of 3
between the aqueous phase of the system (either outside of the
vesicles or inside) and the hydrophobic phospholipid membrane.
The actual driving force for the translocation of 3 across the
phospholipid bilayers is therefore the concentration gradient that
determines the flux of 3 (considering Ficks' first law).
As shown before, the addition of convenient counter ions may
possibly help in bringing highly charged peptides like 1 from one
side of the membrane to the other [38]. Based on studies on
guanidinium-rich α-oligopeptides, the group of Wender [39]
proposed that the translocation of peptides with positively charged
arginine side chains is mediated by the formation of bidentate
hydrogen bonds with a hydrogen bond acceptor functionality on
the surface of the cells. The ion pair thus formed partitions into the
bilayer, followed by amigration across themembrane according to
the transmembrane potential [39]. This hypothesis is similar to the
mechanism described by the group of Matile [38].
5. Conclusion
As a conclusion drawn from previous studies on the trans-
location of a number of different oligopeptides across
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branes (Table 2), there are one or more than one of the following
four mechanistic aspects that are currently assumed to play an
important role for efficient translocation: (i) pore formation that
leads to leaking vesicles; (ii) formation of a complex between the
peptide and the lipids that results in peptide uptake through the
formation of a short-lived “pore”; (iii) role of transmembrane
potential, possibly induced by the initial binding of the peptide to
that half of the bilayer that is exposed to the peptide; (iv) fusion of
the vesicles induced by the peptide. In the case of penetratin and itsTable 2
Selected peptides that are reported to permeate across artificial phospholipid bilayer
Peptide (n=number of
amino acids)
Lipids and bilayer system Ob
Melittin (n=26) egg PC/DNS-PE (9:1) or egg PC/egg
PG/DNS-PE (9:05:0.5); LUVs;
10 mM Tris–HCl, 150 mM NaCl,







LUVs; 10 mM HEPES,
100 mM NaCl or KCl, pH 7.0
Tr
for
Magainin 2 (n=23) egg PC/egg PG/DNS-PE (5:4:1);
LUVs; 10 mM Tris–HCl,
150 mM NaCl, 1 mM EDTA, pH 7
Pe
(ca
Buforin 2 (n=21) and
buforin 2 derivatives
egg PC/egg PG/DNS-PE (50:45:5);
LUVs; 10 mM HEPES, 45 mM NaCl,





Pep-1 (n=21) POPC :POPG (4 :1); LUVs ; 10 mM











GUVs; 5 mM Trizma base,
30 mM K3PO4, 30 mM KH2PO4,




POPC/POPG (3:1); SUVs, LUVs,
GUVs; 100 mM glucose, 10 mM KCl,
0.1 mM EDTA, pH ∼5.5
No
Penetratin analogs PenArg
(n=17) and PenLys (n=17)
POPC/POPG (6:4); LUVs;
10 mM HEPES, 5 mM NaOH, 1 mM
EDTA, 100 mM NaCl, pH 7.4; Soybean
phospholipids (PC/PE/PI/PA/other lipids,
45.7:22.1:18.4:6.9:6.9); GUVs; 5 mM Tris,
10 mM K3POP4. 10 mM KH2PO4,
90 mM KCl, 1 mM MgSO4, 0.5 mM EDTA,
1 mM NaN3, pH 8.1
Pe
Penetratin (n=16) DOPC/DOPG (various molar ratios);
SUVs and LUVs; 10 mM Tris,





Penetratin (n=16) DPPC/cholesterol/SM (50:30:20);




Penetratin (n=16) and other
polybasic peptides (n=6)





Penetratin (n=16) POPC/POPG (3:1); SUVs; 10 mM
phosphate buffer, 154 mM NaF (pH 7.4)
Noderivatives, the situation is not so clear as apparently contradicting
results have been obtained for different lipid systems and
experimental conditions used (Table 2).
Concerning the effect of CPPs on vesicle leakage and transient
pore formation, it has been shown in the case of Tp10 (transportan
10, an analog to transportan containing 21 amino acids) that
calcein leakage from POPC vesicles is dependent on whether the
free peptide is used (Tp10) or a peptide derivative, i. e. Tp10with a
cargo [40]. In the case of Tp10 and cargo-loaded Tp10, it is
suggested that uptake by biological cells occurs via two pathways,s and the suggested translocation mechanism
servations and suggested translocation mechanism Reference
ptide translocation observed in the absence of a
nsmembrane potential; peptide translocation seems to
coupled to “pore” formation (calcein release experiments)
[42]
anslocation is dependent on a membrane potential
med by using valinomycin (K+ inside, Na+ outside the LUVs)
[43]
ptide translocation seems to be coupled to “pore” formation
lcein release experiments)
[44]
ore efficient peptide translocation observed than in the case
magainin 2; no significant membrane destabilization
NTS/DPX leakage assay); proposal for the transient formation of
eptide–lipid supramolecular complex “pore” with a short lifetime
[45,46]
ptide translocation related to the presence of a transmembrane
tential caused by added valinomycin; enhanced translocation by
presence of anionic phospholipids; vesicle aggregation and
id fusion observed. Proposal of the formation of a
ptide–lipid complex during peptide binding to the membrane,
oring peptide translocation without extensive leakage
[47,48]
evidence of “pore” formation (no calcein release) [49]
evidence of peptide translocation [50]
ptide translocation observed across GUVs but not LUVs [51]
lectroporation-like” mechanism proposed for DOPC/DOPGb1,
ording to which the asymmetrical peptide distribution between
ter and inner surfaces causes a transmembrane potential;
evidence of vesicle fusion
[52]
portance of the presence of a transmembrane pH gradient
idic inside the LUVs) for efficient peptide translocation from
inside to the outside
[53]
e uptake mechanism seems to depend on the system used;
ptide translocation dependent on bilayer composition;
sence of transbilayer potential important (K+ inside, Na+ outside
LUVs, use of valinomycin); minimal disturbance of the bilayer
egrity (no calcein release); no evidence of vesicle fusion
[54]
evidence for peptide translocation across the bilayers [55]
2735T. Shimanouchi et al. / Biochimica et Biophysica Acta 1768 (2007) 2726–2736endocytosis and direct membrane interactions, the latter pathway
being more likely of importance in the case of Tp10 containing
small hydrophobic cargos [40].
Our study shows that 3 does not form large pores under the
conditions used (no calcein leakage). Furthermore, vesicle fusion
was not observed. It therefore seems that 3 simply diffuses across
DOPC bilayers.
Recently, it has been proposed that the physico-chemical
translocation of certain CPPs and antimicrobial peptides across
lipid bilayers may occur via a similar mechanism [41]. One quan-
titative difference within the different types of peptides belonging
to the two classes of “membrane active peptides” [41] remains,
however, the extent of pore formation. In this regard, buforin-2
(Table 2) behaves similar to 3: uptake by vesicles without exten-
sive dye leakage.
Since there is no indication that 3 is efficiently taken up by
biological cells — in contrast to 1 [8], we must conclude that
mechanisms other than simple lipid bilayer permeation alone may
be crucial for peptide uptake in living cells [7,8].
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